Loxo Oncology Company Profile (NASDAQ:LOXO)

About Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology logoLoxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. Larotrectinib, formerly referred to as LOXO-101, is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK) family in development for the treatment of tumors with TRK fusions. TRK fusions have been implicated in various tumor types, such as lung cancer, head and neck cancer, melanoma, colorectal cancer, sarcoma, and breast cancer. LOXO-195 is a drug candidate in preclinical development. It was designed as a second-generation TRK inhibitor intended to address predicted acquired resistance mechanisms resulting from therapy with a first-generation TRK inhibitor, such as larotrectinib, or multikinase inhibitors with anti-TRK activity.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:LOXO
  • CUSIP: N/A
  • Web: www.loxooncology.com
Capitalization:
  • Market Cap: $2.09646 billion
  • Outstanding Shares: 26,150,000
Average Prices:
  • 50 Day Moving Avg: $54.92
  • 200 Day Moving Avg: $43.90
  • 52 Week Range: $17.14 - $81.98
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -20.89
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $9.14 per share
  • Price / Book: 8.96
Profitability:
  • EBIDTA: ($86,290,000.00)
  • Return on Equity: -49.23%
  • Return on Assets: -46.67%
Debt:
  • Current Ratio: 23.50%
  • Quick Ratio: 23.50%
Misc:
  • Average Volume: 388,975 shs.
  • Beta: 2.93
  • Short Ratio: 24.83
 

Frequently Asked Questions for Loxo Oncology (NASDAQ:LOXO)

What is Loxo Oncology's stock symbol?

Loxo Oncology trades on the NASDAQ under the ticker symbol "LOXO."

How were Loxo Oncology's earnings last quarter?

Loxo Oncology, Inc. (NASDAQ:LOXO) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by $0.20. View Loxo Oncology's Earnings History.

Where is Loxo Oncology's stock going? Where will Loxo Oncology's stock price be in 2017?

6 equities research analysts have issued 12 month price objectives for Loxo Oncology's shares. Their predictions range from $50.00 to $91.00. On average, they expect Loxo Oncology's share price to reach $74.60 in the next twelve months. View Analyst Ratings for Loxo Oncology.

What are analysts saying about Loxo Oncology stock?

Here are some recent quotes from research analysts about Loxo Oncology stock:

  • 1. According to Zacks Investment Research, "Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. " (6/8/2017)
  • 2. BTIG Research analysts commented, "We have updated our model for LOXO’s 10K, but made no change to our market model for larotrectinib (LOXO-101). We reiterate our Buy Rating and $52 Price Target." (3/12/2017)

Who are some of Loxo Oncology's key competitors?

Who are Loxo Oncology's key executives?

Loxo Oncology's management team includes the folowing people:

  • Joshua H. Bilenker M.D., President, Chief Executive Officer, Director
  • Jennifer Burstein CPA, Vice President - Finance
  • Jacob S. Van Naarden, Chief Business Officer
  • Keith T. Flaherty M.D., Director
  • Lori A. Kunkel M.D., Director
  • David Bonita M.D., Independent Director
  • Steven A. Elms, Independent Director
  • Alan Fuhrman, Independent Director

Who owns Loxo Oncology stock?

Loxo Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Aisling Capital LLC (16.02%), FMR LLC (15.00%), Wellington Management Group LLP (9.32%), Victory Capital Management Inc. (5.09%), Paulson & CO. Inc. (3.11%) and Vanguard Group Inc. (2.80%). Company insiders that own Loxo Oncology stock include Aisling Capital Iii Lp, Avi Z Naider, David P Bonita and Keith T Flaherty. View Institutional Ownership Trends for Loxo Oncology.

Who sold Loxo Oncology stock? Who is selling Loxo Oncology stock?

Loxo Oncology's stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Victory Capital Management Inc., JPMorgan Chase & Co., UBS Asset Management Americas Inc., AXA, Russell Investments Group Ltd., Paulson & CO. Inc. and Morgan Stanley. Company insiders that have sold Loxo Oncology stock in the last year include David P Bonita and Keith T Flaherty. View Insider Buying and Selling for Loxo Oncology.

Who bought Loxo Oncology stock? Who is buying Loxo Oncology stock?

Loxo Oncology's stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Wellington Management Group LLP, Alliancebernstein L.P., State Street Corp, RA Capital Management LLC, Vanguard Group Inc., Driehaus Capital Management LLC and Aisling Capital LLC. Company insiders that have bought Loxo Oncology stock in the last two years include Aisling Capital Iii Lp and Avi Z Naider. View Insider Buying and Selling for Loxo Oncology.

How do I buy Loxo Oncology stock?

Shares of Loxo Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Loxo Oncology's stock price today?

One share of Loxo Oncology stock can currently be purchased for approximately $81.88.


MarketBeat Community Rating for Loxo Oncology (NASDAQ LOXO)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  189
MarketBeat's community ratings are surveys of what our community members think about Loxo Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Loxo Oncology (NASDAQ:LOXO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $74.60 (8.89% downside)

Analysts' Ratings History for Loxo Oncology (NASDAQ:LOXO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/19/2017Morgan StanleyReiterated RatingOverweight$91.00HighView Rating Details
6/6/2017BTIG ResearchReiterated RatingBuy$75.00LowView Rating Details
6/5/2017Cowen and CompanyReiterated RatingOutperformLowView Rating Details
6/5/2017Stifel NicolausBoost Price TargetBuy -> Buy$52.00 -> $71.00HighView Rating Details
6/5/2017Citigroup Inc.UpgradeNeutral -> Buy$86.00HighView Rating Details
2/8/2017Jefferies Group LLCInitiated CoverageBuy$50.00N/AView Rating Details
4/19/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperform$30.00N/AView Rating Details
11/11/2015JMP SecuritiesBoost Price Target$26.00 -> $29.00N/AView Rating Details
(Data available from 6/27/2015 forward)

Earnings

Earnings History for Loxo Oncology (NASDAQ:LOXO)
Earnings by Quarter for Loxo Oncology (NASDAQ:LOXO)
Earnings History by Quarter for Loxo Oncology (NASDAQ LOXO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.76)($0.96)ViewN/AView Earnings Details
3/7/2017Q4 2016($0.85)($1.28)ViewN/AView Earnings Details
11/2/2016Q316($0.74)($0.82)ViewN/AView Earnings Details
8/3/2016Q2($0.63)($0.77)ViewN/AView Earnings Details
5/4/2016Q1($0.69)($0.59)ViewN/AView Earnings Details
3/15/2016Q4($0.53)($0.73)ViewN/AView Earnings Details
11/10/2015Q3($0.53)($0.53)ViewN/AView Earnings Details
8/5/2015Q215($0.45)($0.49)ViewListenView Earnings Details
5/14/2015Q1($0.50)($0.38)ViewN/AView Earnings Details
11/14/2014Q314($0.37)($0.68)ViewN/AView Earnings Details
9/12/2014Q2 2014($12.27)($14.46)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Loxo Oncology (NASDAQ:LOXO)
2017 EPS Consensus Estimate: ($3.68)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.75)($0.75)($0.75)
Q2 20171($0.83)($0.83)($0.83)
Q3 20171($0.92)($0.92)($0.92)
Q4 20171($1.18)($1.18)($1.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Loxo Oncology (NASDAQ:LOXO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Loxo Oncology (NASDAQ:LOXO)
Insider Ownership Percentage: 27.80%
Insider Trades by Quarter for Loxo Oncology (NASDAQ:LOXO)
Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)
Insider Trades by Quarter for Loxo Oncology (NASDAQ:LOXO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2017Keith T FlahertyDirectorSell7,250$45.09$326,902.50View SEC Filing  
1/10/2017Aisling Capital Iii LpMajor ShareholderBuy160,000$31.00$4,960,000.00View SEC Filing  
12/19/2016Keith T FlahertyDirectorSell7,250$30.23$219,167.50View SEC Filing  
9/7/2016Keith T FlahertyDirectorSell14,500$30.00$435,000.00View SEC Filing  
8/11/2016Keith T FlahertyDirectorSell15,000$26.00$390,000.00View SEC Filing  
8/10/2016David P BonitaDirectorSell447,857$26.96$12,074,224.72View SEC Filing  
5/17/2016Aisling Capital Iii LpMajor ShareholderBuy232,558$21.50$4,999,997.00View SEC Filing  
11/17/2015Avi Z NaiderDirectorBuy3,773$26.50$99,984.50View SEC Filing  
11/13/2015Aisling Capital Iii LpMajor ShareholderBuy78,669$27.65$2,175,197.85View SEC Filing  
8/6/2014James E FlynnInsiderBuy1,089,656$13.01$14,176,424.56View SEC Filing  
8/6/2014Orbimed Advisors LlcMajor ShareholderBuy275,385$13.00$3,580,005.00View SEC Filing  
8/6/2014Steve ElmsDirectorBuy413,077$13.00$5,370,001.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Loxo Oncology (NASDAQ:LOXO)
Latest Headlines for Loxo Oncology (NASDAQ:LOXO)
Source:
DateHeadline
americanbankingnews.com logoZacks: Analysts Expect Loxo Oncology, Inc. (LOXO) to Announce -$1.01 Earnings Per Share
www.americanbankingnews.com - June 23 at 10:22 PM
americanbankingnews.com logoLoxo Oncology, Inc. (LOXO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 23 at 12:34 PM
finance.yahoo.com logoFDA to Clear Path for Drugs Aimed at Cancer-Causing Genes
finance.yahoo.com - June 20 at 7:18 PM
finance.yahoo.com logoTrump drug pricing order may be weeks away
finance.yahoo.com - June 20 at 7:18 PM
americanbankingnews.com logoLoxo Oncology, Inc. (LOXO) Stock Rating Reaffirmed by Morgan Stanley
www.americanbankingnews.com - June 19 at 5:38 PM
finance.yahoo.com logoCancer's Big Infrastructure Problem
finance.yahoo.com - June 16 at 7:27 AM
finance.yahoo.com logo[$$] Loxo Strikes While the Biotech Iron is Hot
finance.yahoo.com - June 16 at 7:27 AM
streetinsider.com logoLoxo Oncology (LOXO) Announces Common Offering
www.streetinsider.com - June 13 at 11:31 PM
rttnews.com logoLoxo Oncology Inc. (LOXO) Is Losing Ground On Offering News
www.rttnews.com - June 13 at 6:31 PM
reuters.com logoBRIEF-Loxo Oncology announces proposed public offering of common stock
www.reuters.com - June 13 at 6:31 PM
finance.yahoo.com logoLoxo Oncology Announces Proposed Public Offering of Common Stock
finance.yahoo.com - June 13 at 6:31 PM
finance.yahoo.com logoLoxo Oncology launching secondary offering to fund drug research
finance.yahoo.com - June 13 at 6:31 PM
finance.yahoo.com logoPrecision Oncology Drug Yields Impressive Results, Showing Power Of Cancer Genomics
finance.yahoo.com - June 9 at 9:04 AM
americanbankingnews.com logoLoxo Oncology Inc (LOXO) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - June 8 at 9:44 PM
nasdaq.com logoLOXO Crosses Above Average Analyst Target
www.nasdaq.com - June 6 at 7:01 PM
rttnews.com logoLoxo Oncology Inc. (LOXO) Soared To A New High On Study Results
www.rttnews.com - June 6 at 9:44 AM
americanbankingnews.com logoBTIG Research Reiterates "Buy" Rating for Loxo Oncology Inc (LOXO)
www.americanbankingnews.com - June 6 at 7:58 AM
finance.yahoo.com logoASCO: Loxo Oncology shares up on cancer drug announcement...
finance.yahoo.com - June 6 at 12:05 AM
finance.yahoo.com logoLoxo stock soars on drug trial results: CEO
finance.yahoo.com - June 6 at 12:05 AM
americanbankingnews.com logoLoxo Oncology Inc (LOXO) Given Outperform Rating at Cowen and Company
www.americanbankingnews.com - June 5 at 10:00 PM
nasdaq.com logoLoxo Oncology Inc. (LOXO) Has Leaped To A New High After Publication
www.nasdaq.com - June 5 at 7:03 PM
finance.yahoo.com logoHere Are Winners And Losers From Year's Biggest Cancer Meeting
finance.yahoo.com - June 5 at 7:03 PM
feeds.benzinga.com logo12 Biggest Mid-Day Gainers For Monday
feeds.benzinga.com - June 5 at 12:58 PM
investorplace.com logoLoxo Oncology Inc (LOXO) Shares Skyrocket on Successful Cancer Drug Trial
investorplace.com - June 5 at 12:20 PM
americanbankingnews.com logoLoxo Oncology Inc (LOXO) Raised to "Buy" at Citigroup Inc
www.americanbankingnews.com - June 5 at 11:04 AM
finance.yahoo.com logoLoxo Oncology jumps 34% premarket on news of positive cancer drug trial
finance.yahoo.com - June 5 at 9:39 AM
finance.yahoo.com logoBiotech Movers: Loxo, NewLink, BioCryst
finance.yahoo.com - June 5 at 9:39 AM
americanbankingnews.com logoLoxo Oncology Inc (LOXO) PT Raised to $71.00
www.americanbankingnews.com - June 5 at 9:15 AM
wsj.com logoExperimental Drug Targets Same Genetic Defect Shared by Different Cancers
www.wsj.com - June 4 at 11:30 PM
finance.yahoo.com logoCancer Drug Targeting Rare Mutation Works Across Tumor Types
finance.yahoo.com - June 3 at 5:56 PM
finance.yahoo.com logoA New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us
finance.yahoo.com - June 3 at 5:56 PM
finance.yahoo.com logoLoxo Drug Notches Strikingly High Response Rates in Genetically Defined Tumors
finance.yahoo.com - June 3 at 8:18 AM
finance.yahoo.com logoLoxo Oncology Breakthrough Therapy Larotrectinib Demonstrates 76 Percent Confirmed Objective Response Rate in TRK Fusion Adult and Pediatric Cancers as Presented at the American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - June 3 at 8:18 AM
finance.yahoo.com logoLoxo Oncology Announces Clinical Proof of Concept Publication for Next-Generation TRK Inhibitor LOXO-195
finance.yahoo.com - June 3 at 8:18 AM
finance.yahoo.com logo[$$] Experimental Drug Targets Genetic Defect Shared by Different Cancers
finance.yahoo.com - June 3 at 8:17 AM
americanbankingnews.com logo-$0.97 EPS Expected for Loxo Oncology Inc (LOXO) This Quarter
www.americanbankingnews.com - May 30 at 6:16 PM
reuters.com logoBRIEF-Loxo Oncology announces FDA clearance of investigational new drug application for next-generation trk inhibitor
www.reuters.com - May 30 at 6:04 PM
streetinsider.com logoLoxo Oncology (LOXO) Receives FDA Clearance of IND Application for LOXO-195
www.streetinsider.com - May 30 at 6:04 PM
finance.yahoo.com logoLoxo Oncology Announces FDA Clearance of Investigational New Drug (IND) Application for Next-Generation TRK Inhibitor, LOXO-195
finance.yahoo.com - May 30 at 10:13 AM
americanbankingnews.com logoLoxo Oncology Inc (LOXO) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 29 at 12:47 PM
americanbankingnews.com logoLoxo Oncology Inc (LOXO) Director Keith T. Flaherty Sells 7,250 Shares
www.americanbankingnews.com - May 24 at 7:40 PM
finance.yahoo.com logoLoxo Oncology Announces Details of Two Larotrectinib Clinical Data Oral Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 17 at 6:19 PM
streetinsider.com logoLoxo Oncology (LOXO) Granted Orphan Drug Status for Larotrectinib to Treat Solid Tumors with NTRK-Fusion Proteins
www.streetinsider.com - May 12 at 7:01 PM
reuters.com logoBRIEF-Loxo Oncology announces FDA orphan drug designation granted to larotrectinib
www.reuters.com - May 12 at 7:01 PM
finance.yahoo.com logoLoxo Oncology Announces FDA Orphan Drug Designation Granted to Larotrectinib for the Treatment of Solid Tumors with NTRK-Fusion Proteins
finance.yahoo.com - May 12 at 7:00 PM
americanbankingnews.com logoLoxo Oncology Inc (LOXO) Announces Earnings Results
www.americanbankingnews.com - May 10 at 4:56 PM
reuters.com logoBRIEF-Loxo Oncology announces enrollment of first patient in phase 1 clinical trial of loxo-292
www.reuters.com - May 10 at 12:44 PM
finance.yahoo.com logoLoxo Oncology Announces Enrollment of First Patient in Phase 1 Clinical Trial for Highly Selective RET Inhibitor, LOXO-292
finance.yahoo.com - May 10 at 12:44 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Loxo Oncology, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - May 10 at 12:44 PM
nasdaq.com logoLoxo Oncology Announces First Quarter 2017 Financial Results
www.nasdaq.com - May 9 at 11:57 AM

Social

Chart

Loxo Oncology (LOXO) Chart for Tuesday, June, 27, 2017

This page was last updated on 6/27/2017 by MarketBeat.com Staff